Celularity Inc
CELU1.300USD
+0.130+11.11%
收盘 02/06, 16:00（美东）报价延迟15分钟
36.68M总市值
亏损市盈率 TTM
关于 Celularity Inc 公司
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Inc简介
公司代码CELU
公司名称Celularity Inc
上市日期May 23, 2019
CEOHariri (Robert J)
员工数量123
证券类型Ordinary Share
年结日May 23
公司地址170 Park Ave
城市FLORHAM PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编07932
电话19087682170
网址https://celularity.com/
公司代码CELU
上市日期May 23, 2019
CEOHariri (Robert J)
Celularity Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月3日 周六
更新时间: 1月3日 周六
持股股东
股东类型
持股股东
持股股东
占比
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
其他
55.90%
持股股东
持股股东
占比
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
其他
55.90%
股东类型
持股股东
占比
Corporation
26.24%
Individual Investor
15.43%
Investment Advisor
8.72%
Insurance Company
2.65%
Investment Advisor/Hedge Fund
1.30%
Hedge Fund
0.38%
Research Firm
0.17%
Family Office
0.04%
其他
45.07%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
71
3.81M
13.22%
-291.61K
2025Q3
80
3.82M
16.36%
+119.97K
2025Q2
92
3.70M
17.46%
+189.07K
2025Q1
120
3.51M
18.18%
-579.52K
2024Q4
135
3.39M
17.70%
+120.20K
2024Q3
149
3.27M
18.60%
+20.75K
2024Q2
160
3.32M
18.56%
+109.90K
2024Q1
166
3.20M
18.29%
-780.71K
2023Q4
164
3.20M
20.76%
-511.70K
2023Q3
164
3.71M
20.21%
+96.25K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Genting Bhd
6.34M
22.25%
--
--
Oct 30, 2025
Hariri (Robert J)
2.86M
10.04%
+3.28K
+0.11%
Oct 30, 2025
Starr International Company, Inc.
1.53M
5.37%
--
--
Oct 30, 2025
Lincoln Alternative Strategies LLC
1.23M
4.32%
+1.23M
--
Jul 14, 2025
C.V. Starr & Co., Inc.
764.07K
2.68%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
676.65K
2.38%
+176.52K
+35.29%
Sep 30, 2025
Ling (Geoffrey M. D.)
472.29K
1.66%
+192.42K
+68.75%
Dec 29, 2025
Diamandis (Peter)
441.18K
1.55%
+192.42K
+77.35%
Dec 29, 2025
Parks (Diane L.)
344.98K
1.21%
+192.42K
+126.12%
Dec 29, 2025
Levien (Vincent)
128.70K
0.45%
+125.00K
+3379.29%
Dec 29, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
公告日期
除权除息日
类型
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
